-
Mashup Score: 1
Stereotactic body radiation therapy combined with single-dose durvalumab before surgery appeared safe and induced durable responses among patients with HPV-unrelated locally advanced head and neck cancer, according to study results.The findings of the phase 1/1b study, published in Nature Cancer, laid the groundwork for a larger, ongoing phase 2 trial.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Docetaxel plus radiation new standard of care in cisplatin-ineligible head and neck cancer - 1 year(s) ago
CHICAGO — Docetaxel prolonged DFS and OS when added to radiation for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma, according to study results presented at ASCO Annual Meeting.The addition of docetaxel also did not appear to worsen quality of life at 6 months, researchers concluded.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Circulating tumor HPV DNA testing has limitations for diagnosis of oropharynx cancers - 1 year(s) ago
Circulating tumor tissue-modified viral HPV DNA detected through a new assay appeared associated with nodal disease burden among patients with HPV-positive oropharyngeal squamous cell carcinoma, according to study results.The findings, published in JAMA Otolaryngology Head and Neck Surgery, showed the assay did not detect clinical stage N0 disease; thus, sensitivity of the assay may be lower
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Adding panitumumab vs. bevacizumab to chemotherapy extends OS in colorectal cancer subset - 1 year(s) ago
The addition of panitumumab vs. bevacizumab to standard first-line chemotherapy significantly extended OS for certain patients with RAS wild-type metastatic colorectal cancer, according to data published in JAMA. “Although this study showed significant improvement of survival in the overall population, subgroup analysis suggested no significant difference in overall survival between
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Results of a survey study showed a decrease in the proportion of Americans who are aware that HPV causes cervical cancer, according to a presenter at American Association for Cancer Research Annual Meeting. Additionally, fewer than one-third of survey respondents knew that HPV can cause anal, oral and penile cancers, according to the data.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.Omidubicel-onlv (Omisirge, Gamida Cell) is indicated for adults and children aged over 12 years with blood cancers planned for umbilical cord blood transplantation after a
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1AACR names president-elect for 2023-2024 - 1 year(s) ago
Patricia M. LoRusso, DO, PhD (hc), has been elected president-elect of American Association for Cancer Research for 2023-2024.LoRusso began her term on April 17.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
The addition of pembrolizumab to gemcitabine and cisplatin conferred a statistically significant and clinically meaningful survival benefit for patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 study. “We were encouraged to see the consistency of benefit across geographic regions, including non-Asian regions, and across PD-L1 expression
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Perioperative durvalumab-based therapy reduces risk for adverse lung cancer outcomes - 1 year(s) ago
Patients with resectable non-small cell lung cancer who received perioperative durvalumab with neoadjuvant chemotherapy had significantly longer EFS and higher pathologic complete response rates than those who received chemotherapy alone.The combination also had a manageable safety profile consistent with previous studies, according to results of the randomized, double-blind phase 3 AEGEAN trial,
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0St. Jude Children’s Research Hospital appoints chair of epidemiology, cancer control - 1 year(s) ago
Greg Armstrong, MD, MSCE, has been named chair of the department of epidemiology and cancer control at St. Jude Children’s Research Hospital.Armstrong — a Healio | HemOnc Today Editorial Board member — is recognized for his expertise in childhood cancer survivorship.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
ICYMI: Less-invasive treatment identified for HPV-unrelated head and neck cancer. https://t.co/fm52uCJK3U #HeadNeckCancerAwarenessMonth #HeadNeckCancer #HemOnc #OncAlert #MedEd